SCHEDULE: Novo Holdings Discloses 9% Stake in Hemab Therapeutics

Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Summary

• Novo Holdings A/S, a Danish investment firm wholly owned by the Novo Nordisk Foundation, has filed a Schedule 13G.
• The filing indicates that Novo Holdings A/S beneficially owns 4,180,550 shares of Hemab Therapeutics Holdings, Inc. common stock.
• This ownership represents 9.0% of the class of securities.
• The date of the event requiring this filing is June 30, 2026.
• Novo Holdings A/S has sole voting power and sole dispositive power over these shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new financial or strategic information.

Positives

• Novo Holdings A/S, a significant life sciences investor, has taken a substantial stake in Hemab Therapeutics, potentially signaling confidence in the company's prospects.
• The clear disclosure of ownership provides transparency to the market regarding a major shareholder.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Hemab Therapeutics, limiting insight into the company's operational health.
• The nature of the investment (passive stake) does not inherently guarantee future support or involvement from Novo Holdings A/S.

Risks

• The filing is a Schedule 13G, indicating passive investment, meaning Novo Holdings A/S may not actively seek to influence management or operations, which could limit strategic support.
• Future changes in Novo Holdings A/S's investment strategy could lead to a disposition of shares, potentially impacting Hemab Therapeutics' stock price.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Hemab Therapeutics' future performance. It solely reports on beneficial ownership.

Management Comments

• Barbara Fiorini, General Counsel, Finance & Operations for Novo Holdings A/S, certified the accuracy of the filing.

Industry Context

StockSavvy.ai notes that Novo Holdings A/S is a prominent investor in the life sciences sector. Their acquisition of a significant stake in Hemab Therapeutics suggests a potential validation of Hemab's technology or market position within the competitive biotechnology landscape.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake, which could influence market perception.
• Management: May see Novo Holdings A/S as a potential strategic partner or source of future investment, though the passive nature of the filing limits immediate impact.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Novo Holdings A/S will continue to hold its stake in Hemab Therapeutics unless its investment strategy changes.
• Hemab Therapeutics will continue its operations and strategic initiatives as planned.

Key Dates

Keywords

Hemab Therapeutics, Novo Holdings, Schedule 13G, Beneficial Ownership, Investment, Life Sciences, Denmark, Novo Nordisk Foundation